2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.42 (Poster) Mutation/ Co-mutation Characteristics and Clinical Outcomes for Lung Adenocarcinoma with EGFR Germline Mutations

PP01.42 (Poster) Mutation/ Co-mutation Characteristics and Clinical Outcomes for Lung Adenocarcinoma with EGFR Germline Mutations

Back to course

Pdf Summary

This study focused on the characteristics and outcomes of lung adenocarcinoma patients with germline mutations in the EGFR gene. The researchers analyzed data from 22 patients diagnosed with non-small cell lung cancer (NSCLC) who underwent molecular profiling through next-generation sequencing. They found that germline EGFR mutations were more common in female patients (86.4%), non-smokers (81.8%), and Caucasians (86.4%). Additionally, a majority of the patients had a family history of lung cancer (59.1%) and were diagnosed with advanced-stage disease (81.8%). Radiographic imaging showed a distinct pattern of small multifocal ground-glass nodules in most patients.<br /><br />The most common somatic mutation observed in this germline cohort was EGFR exon 21 L858R, present in 50% of the patients. The researchers noted that osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), was an effective treatment option for patients with germline EGFR-mutated advanced NSCLC, leading to similar survival outcomes as classical EGFR-mutated NSCLC. However, further studies are required to evaluate the potential of CT screening and EGFR TKIs for cancer interception in individuals with germline EGFR mutations.<br /><br />This study provides valuable insights into the clinical characteristics and management of lung adenocarcinoma patients with EGFR germline mutations. The findings highlight the importance of genetic testing in identifying potential germline mutations in lung cancer patients, as it can influence treatment decisions and prognosis. The results also support the use of osimertinib as a systemic therapy for advanced-stage germline EGFR-mutated NSCLC. The researchers suggest that future research should focus on determining the utility of CT screening and EGFR TKIs in the early detection and prevention of cancer in individuals with germline EGFR mutations.

Asset Subtitle

Kelsey Pan

Keywords

lung adenocarcinoma

germline mutations

EGFR gene

non-small cell lung cancer

molecular profiling

next-generation sequencing

female patients

non-smokers

Caucasians

family history